Will Maduck or Mokari file a Form 4 sale below $40 by 2026-09-30?

Decomposition: P(Maduck or Mokari executes any Form 4 sale by 9/30) AND P(execution price below $40 | sale occurs). First probability is ~0.55-0.70 given plans have cleared cooling-off (March 2026) and both have pipeline Form 144 volume. Second probability is ~0.35-0.50 depending on plan design. Typical rational plan design for officers under reputational scrutiny: price floors at $42-48 (sell-into-strength) that avoid sub-$40 execution specifically to avoid the MISALIGNED optics escalation. But CORT traded at $33-45 through March-April 2026, so any non-floor execution would be sub-$40. Joint probability: ~0.60 * 0.50 = 0.30. Ticker currently ~$45 makes sub-$40 execution less likely for price-triggered plans. Net: 0.32.

A different view: the timing of plan adoption (18-22 days pre-CRL, stock in $55-65 range at adoption) suggests plans may have been designed with triggers in the $45-55 range (then-plausible sale targets), not $40+ (protect from MISALIGNED optics). If that's the case, plans may actually be structured to execute at current price levels. Additionally, Maduck 600K + Mokari 200K = 800K shares is substantial volume that requires multiple execution tranches over many quarters; the first tranche is likely to execute relatively soon after cooling-off clears (March 2026). Over a 6-month window (March - September), at least one tranche execution is highly probable if plans are time-based or low-floor price-based. Probability 0.40.

Risk of reputational cost is important. Maduck is CFO and Mokari is a named executive in the compensation disclosure - both are visible to SEC, analysts, plaintiffs' bar (Ritchie derivative suit adds heightened scrutiny). A sub-$40 Form 4 execution within 6 months of cooling-off (when plan adoption timing is already under scrutiny for MNPI) would generate board-level concern. Rational actor theory says they would have designed plans with floors or restricted sales to above-market periods. Baker's $3.3M buy at $33.14 is a co-existing signal that SOMEONE at the company thought sub-$35 was attractive buying territory - if Maduck/Mokari execute below $40 in parallel, it creates dissonant insider narrative. Probability 0.30 reflects that executive-level rationality argues for price-protected structures.

10b5-1 plans cleared cooling-off in March 2026. Stock traded $33-45 range in March-April. If plans have low or no price floors, first-tranche execution at sub-$40 is probable. If plans have $42+ floors, sub-$40 execution requires another dip. Typical specialty pharma officer plans: mix of time-based and price-filtered with floors near current or above. Probability balances these scenarios at 0.35.

Baseline: 800K combined shares is large enough that time-based execution over the plan window would produce Form 4 filings even without price triggers. If any time-based component triggered execution during March-April (when stock was $33-45), sub-$40 execution was likely. If fully price-filtered with $40+ floor, sub-$40 requires future dip. Probability 0.38 reflects uncertainty on plan structure.

I lean on the rational actor argument. Officers subject to existing derivative litigation who have designed plans under MNPI scrutiny would most naturally include price floors to avoid sub-$40 execution specifically. The $40 threshold is a schelling point that officers would anticipate being tested by observers. Probability 0.30.

Plans cleared cooling-off March 2026. Stock $33-45 range in March-April. Large volume (800K combined) likely has time-based component. Some sub-$40 execution probable over 6 months. Probability 0.35.

Rational officers under scrutiny design plans with floors above $40 to avoid optics issue. Probability of sub-$40 execution is lower-end. Net 0.30.

Stock recent range includes sub-$40. 6-month window long enough for multiple execution opportunities. Plan structure uncertainty pulls probability toward middle range. Net 0.37.